Selling, General, and Administrative Costs: Novo Nordisk A/S vs CymaBay Therapeutics, Inc.

A Tale of Two Companies: SG&A Expenses Over Time

In the world of pharmaceuticals, managing costs is as crucial as innovation. This chart provides a fascinating glimpse into the Selling, General, and Administrative (SG&A) expenses of two industry players: Novo Nordisk A/S and CymaBay Therapeutics, Inc., from 2014 to 2023.

Novo Nordisk, a global leader in diabetes care, consistently outpaces CymaBay in SG&A expenses, reflecting its expansive global operations. In 2023, Novo Nordisk's SG&A expenses were approximately 6.16 trillion, marking a 130% increase from 2014. Meanwhile, CymaBay, a smaller biotech firm, saw its SG&A expenses grow by over 530% during the same period, reaching 51.95 million in 2023.

This stark contrast highlights the differing scales and strategies of these companies. While Novo Nordisk's expenses reflect its established market presence, CymaBay's rising costs may indicate its aggressive push for growth and market penetration.